<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03148366</url>
  </required_header>
  <id_info>
    <org_study_id>201410001MINC</org_study_id>
    <nct_id>NCT03148366</nct_id>
  </id_info>
  <brief_title>Comparison of the Levofloxacin Sequential Therapy and Quadruple Therapy in Second Line Treatment for HP</brief_title>
  <official_title>Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Bismuth Quadruple Therapy in the Second Line and Third Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: Eradication of H. pylori infection could reduce the occurence or recurrence of&#xD;
      gastric cancer and peptic ulcer diseases. However, it was estimated that 15-20% of patients&#xD;
      would fail from first line standard eradication therapy and need second line rescue therapy.&#xD;
      About 15-30% of patient would fail from second line therapy. Bismuth quadruple therapy and&#xD;
      triple therapy containing levofloxacin are currently the recommended rescue therapies in the&#xD;
      second line and third line treatment. Recently, our pilot study showed that modified&#xD;
      sequential therapy containing levofloxacin achieved high eradication rate (95%) in the second&#xD;
      line therapy. The regimen includes a PPI plus amoxicillin for 5-7 days, followed by a PPI&#xD;
      plus levofloxacin and metronidazole for another 5-7 days. However, whether this modified&#xD;
      sequential therapy containing levofloxacin is more effective than bismuth quadruple therapy&#xD;
      in the second line and third line treatment remains unknown. Besides, the impact of these&#xD;
      regimens on the antibiotic resistance , microbiota of gut flora, and metabolic factors&#xD;
      remains unknown.&#xD;
&#xD;
      Aims: Therefore, the investigators aimed to&#xD;
&#xD;
        1. compare the eradication rates and long term re-infection rates of sequential therapy&#xD;
           containing levofloxacin for 14 days versus bismuth quadruple therapy for 10 days in the&#xD;
           second line and third line treatment&#xD;
&#xD;
        2. assess the impact of antibiotic resistance and CYP2C19 polymorphism on the eradication&#xD;
           rate of these regimens&#xD;
&#xD;
        3. assess the impact of these eradication regimens on the antibiotic resistance and&#xD;
           microbiota of the gut flora&#xD;
&#xD;
        4. assess the impact of eradication therapy on the metabolic factors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods:&#xD;
&#xD;
      This will be a multi-center, open labeled, randomized comparative trial with cross-over&#xD;
      design Patients: Participants with refractory H. pylori infection after one eradication&#xD;
      therapy&#xD;
&#xD;
      Testing for H. pylori infection Before Second Line Treatment : Any two positive of CLO test,&#xD;
      histology, and culture or a positive UBT will be considered as H. pylori infected&#xD;
&#xD;
      After Second Line Treatment: C13-UBT will be used to assess the existence of H. pylori 6-8&#xD;
      weeks after first line therapy.&#xD;
&#xD;
      Long term reinfection: C13-UBT will be used to assess the recurrence of H. pylori 1 year&#xD;
      after eradication therapy&#xD;
&#xD;
      Interventions:&#xD;
&#xD;
      Second line therapy: eligible patients will be randomized into one of the two groups Group&#xD;
      (A): sequential therapy containing levofloxacin for 14 days (EAML) D1-D7: (esomeprazole 40mg&#xD;
      bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid&#xD;
      + metronidazole 500mg bid) for another 7 days&#xD;
&#xD;
      Group (B): bismuth quadruple therapy for 10 days (BQ) D1-D10: (esomeprazole 40mg bid +&#xD;
      Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days&#xD;
&#xD;
      Third line therapy: patients who fail from second line treatment will be rescue with the&#xD;
      following treatment Group (A) Patient who fail from levofloxacin sequential therapy will be&#xD;
      retreated with bismuth quadruple therapy for 10 days D1-D10: (esomeprazole 40mg bid +&#xD;
      Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days&#xD;
&#xD;
      Group (B) Patient who fail from bismuth quadruple therapy will be retreated with levofloxacin&#xD;
      sequential therapy for 14days D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days&#xD;
      D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for&#xD;
      another 7 days&#xD;
&#xD;
      Outcome Measurement:&#xD;
&#xD;
      Primary End Point: Eradication rate in the second line according to intention to treat (ITT)&#xD;
      and per-protocol (PP) analysis in the two treatment groups&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate after second line eradication therapy according to ITT analysis</measure>
    <time_frame>6 weeks after completion of treatment</time_frame>
    <description>The eradication status will be determined by urea breath test (UBT) at least 6 weeks after completion of the treatment. The delta value of UBT of 4 or less will be defined as negative and successful eradication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects during eradication therapy</measure>
    <time_frame>during treatment (2 weeks)</time_frame>
    <description>adverse effects will be assessed by questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term eradication rate 1 year after eradication therapy</measure>
    <time_frame>1 year after treatment</time_frame>
    <description>Long term eradication rates will be determined by UBT at 1 year after eradication therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of gut microbiota before and after eradication therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Fecal DNA will be extracted and 16S rRNA sequencing will be done. The changes in the alpha and beta diversity and the compositions of gut microbiota before and after HP eradication will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Helicobacter</condition>
  <arm_group>
    <arm_group_label>Levofloxacin based sequential therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levofloxacin based sequential therapy&#xD;
: sequential therapy containing levofloxacin for 14 days D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bismuth quadruple therapy (BQ)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bismuth quadruple therapy for 10 days (BQ) D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin based sequential therapy</intervention_name>
    <description>D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days</description>
    <arm_group_label>Levofloxacin based sequential therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bismuth quadruple therapy for 10 days (BQ)</intervention_name>
    <description>D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days</description>
    <arm_group_label>bismuth quadruple therapy (BQ)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. H. pylori infected patients who failed from first line standard triple therapy with&#xD;
        clarithromycin, amoxicillin, and a proton pump inhibitor were eligible in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. children and teenagers aged less than 20 years,&#xD;
&#xD;
          2. history of gastrectomy,&#xD;
&#xD;
          3. gastric malignancy, including adenocarcinoma and lymphoma,&#xD;
&#xD;
          4. previous allergic reaction to antibiotics (bismuth, metronidazole, levofloxacin,&#xD;
             tetracycline) and PPI (esomeprazole),&#xD;
&#xD;
          5. contraindication to treatment drugs,&#xD;
&#xD;
          6. pregnant or lactating women,&#xD;
&#xD;
          7. severe concurrent disease, or&#xD;
&#xD;
          8. Unwilling to accept random assignment of subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Shiang Wu</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jyh-Ming Liou</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyh-Ming Liou, MD, PhD</last_name>
    <email>dtmed046@pchome.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Shiang Wu</last_name>
    </contact>
    <contact_backup>
      <last_name>Jyh-Ming Liou</last_name>
    </contact_backup>
    <investigator>
      <last_name>Chieh-Chang Chang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jyh-MIng Liou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yunlin branch</name>
      <address>
        <city>Yunlin</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Jen Fang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2013 Jan 19;381(9862):205-13. doi: 10.1016/S0140-6736(12)61579-7. Epub 2012 Nov 16. Erratum in: Lancet. 2013 Apr 13;381(9874):1276.</citation>
    <PMID>23158886</PMID>
  </results_reference>
  <results_reference>
    <citation>Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ, Hsu YC, Tseng CH, Tseng PH, Chang L, Chang WH, Wang HP, Shun CT, Wu JY, Lee YC, Lin JT, Wu MS; Taiwan Helicobacter Consortium. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2013 Feb;68(2):450-6. doi: 10.1093/jac/dks407. Epub 2012 Oct 25.</citation>
    <PMID>23099849</PMID>
  </results_reference>
  <results_reference>
    <citation>Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2011 Aug;66(8):1847-52. doi: 10.1093/jac/dkr217. Epub 2011 May 31.</citation>
    <PMID>21632579</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Self Efficacy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators will not share the data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

